Galangin Mitigates Allergic Rhinitis
Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
Variable analysis
- Administration of OVA (500 μL, 5%, IP) on alternate days till day 14
- Treatment with distilled water (DW; 10 mg/kg, PO), montelukast (10 mg/kg, PO), and galangin (5, 10, and 20 mg/kg, PO) till day 21
- Nasal symptoms evaluated on day 21
- Normal group of mice received aluminum hydroxide IP without OVA and was treated with DW (10 mg/kg)
- Per se group received galangin (20 mg/kg) only till day 21
- Positive control: Normal group of mice received aluminum hydroxide IP without OVA and was treated with DW (10 mg/kg)
- Negative control: Per se group received galangin (20 mg/kg) only till day 21
Annotations
Based on most similar protocols
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!